Factory 99% Carbidopa Monohydrate Powder CAS 38821-49-7 Antitumor Carbidopa

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A167
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Carbidopa Monohydrate
• Appearance: White Powder
• Assay: 99%
• CAS: 38821-49-7
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 100g
• Function: Antitumor
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Carbidopa Monohydrate
Appearance	White Powder
CAS NO.	38821-49-7
Molecular Formula	C10H16N2O5
Storage	Keep in a cool, dry, dark location

 

Carbidopa Monohydrate is a peripheral decarboxylase inhibitor that is commonly used in combination with levodopa to treat Parkinson's disease. It is a selective aryl hydrocarbon receptor (AhR) modulator and has been shown to inhibit pancreatic cancer cell and tumor growth in research settings.

 

 

1. Parkinson's Disease Treatment: Carbidopa Monohydrate is primarily used in combination with levodopa to enhance the effectiveness of levodopa by inhibiting its peripheral metabolism, allowing more levodopa to reach the brain.
2. Cancer Research: In research settings, Carbidopa Monohydrate has been investigated for its potential to inhibit cancer cell growth, particularly in pancreatic cancer.
3. Pharmaceutical Development: There may be ongoing efforts to develop new formulations or indications for Carbidopa Monohydrate based on its unique pharmacological properties.

1. Decarboxylase Inhibition: Carbidopa Monohydrate inhibits the peripheral decarboxylation of levodopa, preventing its conversion to dopamine outside the brain. This allows for more effective delivery of levodopa to the central nervous system.
2. AhR Modulation: As a selective aryl hydrocarbon receptor (AhR) modulator, Carbidopa Monohydrate may regulate gene expression and cellular responses to environmental stimuli, including those related to cancer development.
3. Antitumor Activity: In vitro and in vivo studies have demonstrated that Carbidopa Monohydrate can inhibit the growth of certain cancer cells, including pancreatic cancer cells, through mechanisms that are not fully understood but may involve AhR-mediated pathways.